Can Teladoc (NYSE:) be heading for an intervention by an activist investor? Analysts at Jefferies consider so.
There isn’t any denying the telemedicine firm can use a change in fact – its shares are down over 96% because the pandemic highs, and have misplaced almost 50% by the primary half of 2024 alone.
Analysts at Jefferies, of their most up-to-date word, reiterated their doubts within the firm’s present technique.
They word that “BetterHelp growth has been disappointing,” and whereas “Integrated Care has pillared the growth & margin expansion,” they nonetheless have questions over “the LT demand for chronic and primary care services.”
As such, the analysts voice their considerations that the present administration seems to “believe the company has the right assets/strategy, and is just in need of operational leadership,” whereas they see the necessity for an “overall strategic review,” with the intention to restructure productive property and reduce pointless prices.
They conclude: “With leadership in transition, & the average Board tenure at 6.2 yrs, with 6 of 9 members pre-dating the Livongo trans, shares seem ripe for structural change. An activist could influence the CEO decision, claim some Board seats, & be instrumental in reshaping the strategy.”
Jefferies reiterated a Maintain ranking on the shares, however lowered the Worth Goal to $10 from $14.
